Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Paving New Regs: Firms Petition For Smoother Ride For Off-Label Communications

  • News

You may also be interested in...



When Is On-Label Speech Off-Label Promotion? Par Links The Two In Suit Against FDA

Par Pharmaceutical Inc.’s First Amendment suit against FDA offers a new approach to battling government allegations of off-label marketing.

When Is On-Label Speech Off-Label Promotion? Par Links The Two In Suit Against FDA

Par Pharmaceutical Inc.’s First Amendment suit against FDA offers a new approach to battling government allegations of off-label marketing.

Par Sues FDA To Get "Tailored" Rules On Off-Label Promotion

Par claims it is being blocked from informing physicians about the approved use of Megace ES; the case could be derailed by a DoJ complaint against Par, as was Allergan's suit against FDA.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities

News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR

GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health

FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility

See All
UsernamePublicRestriction

Register

PS053580

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By